Back to Journals » ImmunoTargets and Therapy » Volume 2

Allergen immunotherapy: routes, safety,efficacy, and mode of action

Authors Hochfelder JL, Ponda P

Received 10 April 2013

Accepted for publication 5 June 2013

Published 23 July 2013 Volume 2013:2 Pages 61—71


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 5

Jillian Leigh Hochfelder, Punita Ponda

Division of Allergy and Immunology, North Shore–Long Island Jewish Health System, New Hyde Park, NY, USA

Abstract: Allergic rhinitis, allergic conjunctivitis, and allergic asthma have been steadily increasing in prevalence in recent years. These allergic diseases have a major impact on quality of life and are a major economic burden in the US. Although allergen avoidance and pharmacotherapy are currently the mainstays of therapy, they are not always successful in treating patients’ symptoms effectively. If a patient fails allergen avoidance and medical therapy, immunotherapy may be indicated. Furthermore, immunotherapy is the only therapy that may change the course of the disease and induce long-term remission. Though subcutaneous administration has been the standard route for immunotherapy for many decades, there are several other routes of administration that have been and are currently being studied. The goal of utilizing alternative routes of immunotherapy is to improve safety without decreasing the efficacy of treatment. This paper will review the novel routes of immunotherapy, including sublingual, oral, local nasal, epicutaneous, and intralymphatic.

Keywords: immunotherapy, allergic rhinitis, allergic asthma, sublingual, intralymphatic

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]